PMID- 20684157
OWN - NLM
STAT- MEDLINE
DCOM- 20100819
LR  - 20220317
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 9
IP  - 8
DP  - 2010 Aug
TI  - Development of subacute cutaneous lupus erythematosus associated with the use of 
      imiquimod to treat actinic keratoses.
PG  - 1022-4
AB  - The immunomodulating drug imiquimod is approved by the U.S. Food and Drug 
      Administration (FDA) to treat actinic keratoses, non-facial superficial basal 
      cell carcinomas and genital warts. This drug elicits its immunological response 
      by binding to toll-like receptor 7 (TLR-7) on dendritic cells inducing the 
      production of interferon alpha (IFN-alpha) and other inflammatory cytokines. The 
      authors report the case of a 56-year-old female who developed subacute cutaneous 
      lupus erythematosus (SCLE), as well as severe autoimmune retinitis following a 
      vigorous response to imiquimod 5% cream that was prescribed to treat actinic 
      keratoses. Given the important role of IFN-alpha in the pathogenesis of cutaneous 
      lupus, it is likely that imiquimod either induced or unmasked an autoimmune 
      tendency in this patient.
FAU - Burnett, Thomas J
AU  - Burnett TJ
AD  - United States Air Force, WPAFB, OH, USA.
FAU - English, Joseph C 3rd
AU  - English JC 3rd
FAU - Ferris, Laura Korb
AU  - Ferris LK
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Aminoquinolines)
RN  - P1QW714R7M (Imiquimod)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage/*adverse effects/therapeutic use
MH  - Administration, Cutaneous
MH  - Aminoquinolines/administration & dosage/*adverse effects/therapeutic use
MH  - Autoimmune Diseases/chemically induced
MH  - Female
MH  - Humans
MH  - Imiquimod
MH  - Keratosis, Actinic/drug therapy
MH  - Lupus Erythematosus, Cutaneous/*chemically induced
MH  - Middle Aged
MH  - Retinitis/chemically induced/immunology
MH  - Severity of Illness Index
EDAT- 2010/08/06 06:00
MHDA- 2010/08/20 06:00
CRDT- 2010/08/06 06:00
PHST- 2010/08/06 06:00 [entrez]
PHST- 2010/08/06 06:00 [pubmed]
PHST- 2010/08/20 06:00 [medline]
PST - ppublish
SO  - J Drugs Dermatol. 2010 Aug;9(8):1022-4.